Drug maker Amgen reported “encouraging results” from its Phase II trial of the experimental cancer drug AMG-706, which treats a type of gastrointestinal cancer. The Thousand Oaks company tested the product on 138 patients with gastrointestinal stromal tumors who stopped responding to Gleevec, a drug by Novartis. The study found that 24 percent of patients had symptoms level out and 3 percent has their tumors shrink.
